Pacific Edge Limited (NZE:PEB)

Market Cap	179.98M +64.2%
Revenue (ttm)	18.24M -19.4%
Net Income	-34.55M
EPS	-0.04
Shares Out	1.02B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,624,809
Average Volume	352,682
Open	0.1820
Previous Close	0.1830
Day's Range	0.1760 - 0.1830
52-Week Range	0.0780 - 0.3050
Beta	0.80
RSI	39.89
Earnings Date	May 25, 2026

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: PEB

Financial Performance

In fiscal year 2025, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2024.